Shareholder Votes

New Fortress Energy Inc. shareholders approved Provide for election of directors by a majority of the total votes that may be cast in the election of directors by holders of all issued and outstanding shares of the Company entitled to vote.

“b. To provide for the election of directors by a majority of the total votes that may be cast in the election of directors by holders of all issued and outstanding shares of the Company entitled to vote. Votes For Votes Against Abstentions Broker Non-Votes 187,197,237 748,145 441,214 41,290,053”

New Fortress Energy Inc. shareholders approved Remove existing staggered board.

“a. To remove the existing staggered board. Votes For Votes Against Abstentions Broker Non-Votes 187,111,180 714,383 561,033 41,290,053”

New Fortress Energy Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-12-31 meeting.

“2. The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions 227,490,080 1,255,435 931,134”

New Fortress Energy Inc. shareholders approved Election of two Class I directors to serve until the 2029 Annual Meeting.

“1. The Company’s stockholders elected two Class I directors, who comprise all the directors of such class, to serve until the 2029 Annual Meeting of Stockholders and until their respective successors are duly elected or appointed and qualified. Director Nominee Votes For Votes Withheld Broker Non-Votes Charles M. Sledge 181,631,718 6,754,878 41,290,053 Katherine E. Wanner 177,661,748 10,724,848 41,290,053”

Amprius Technologies, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.

“Proposal 2 – Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 Votes For Votes Against Abstentions Broker Non-Votes 96,014,911 85,854 981,391 —”

Amprius Technologies, Inc. shareholders approved Election of two directors to serve until the 2029 annual meeting of stockholders at the 2026-06-11 meeting.

“Proposal 1 – Election of two directors to serve until the 2029 annual meeting of stockholders Director Votes For Votes Withheld Broker Non-Votes Kathleen Bayless 50,367,535 20,194,821 26,519,800 Thomas M. Stepien 53,880,993 16,681,363 26,519,800”

Aprea Therapeutics, Inc. shareholders approved A proposal to approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3. at the 2026-06-16 meeting.

“The Company’s stockholders voted to approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 8,056,154 191,486 20,811 0”

Aprea Therapeutics, Inc. shareholders approved A proposal to approve, by non-binding advisory vote, the frequency of future votes on the compensation of the Company’s named executive officers. at the 2026-06-16 meeting.

“The Company’s stockholders voted to approve, by non-binding advisory vote, the frequency of future votes on the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: 1 Year 2 Years 3 Years Votes Abstaining 4,276,181 22,984 1,056,208 526,693”

Aprea Therapeutics, Inc. shareholders approved A proposal to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers. at the 2026-06-16 meeting.

“The Company’s stockholders voted to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 5,777,837 78,853 25,376 2,386,385”

Aprea Therapeutics, Inc. shareholders approved A proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, and to authorize the Board of Directors of the Company (the “Board”) to effect a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a ratio of not at the 2026-06-16 meeting.

“The Company’s stockholders voted to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, and authorized the Board to effect a reverse stock split of the Common Stock at a ratio of not less than one-for-three and not more than one-for-eight of the Common Stock (with all fractional shares rounded up to the nearest whole share) (the “Reverse Stock Split”), with the exact ratio to be set within this range by the Board in its sole discretion (without reducing the authorized number of shares of the Common Stock), and with the Reverse Stock Split to be effected at such time and date, if at all, as determined by the Board in its sole discretion (“Proposal 3”). The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 8,038,052 210,751 19,648 0”

Aprea Therapeutics, Inc. shareholders approved A proposal to ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year. at the 2026-06-16 meeting.

“The Company’s stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year 2026. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 8,107,969 44,299 116,183 0”

Aprea Therapeutics, Inc. shareholders approved A proposal to elect three Class I directors of the Company, Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D., each to hold office until the 2029 Annual Meeting of Stockholders or until their respective successors shall have been duly elected and qualified. at the 2026-06-16 meeting.

“The Company’s stockholders elected the following directors to serve as Class I directors until the 2029 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. The votes regarding the election of the directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Marc Duey 5,817,488 64,578 2,386,385 Richard Peters, M.D. 5,824,115 57,951 2,386,385 Bernd R. Seizinger, M.D., Ph.D. 5,495,110 386,956 2,386,385”

Hepion Pharmaceuticals, Inc. shareholders approved Approve an amendment to the Company’s 2023 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 8,000,000 from 200,000. at the 2026-06-17 meeting.

“To approve an amendment to the Company’s 2023 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 8,000,000 from 200,000. Votes For Votes Against Votes Abstained Broker Non-Vote 13,442,072 208,879 1,751 4,816,704”

Hepion Pharmaceuticals, Inc. shareholders approved Ratify the appointment of Grassi & Co., CPAs, P.C, as the Company’s independent auditors for the fiscal year ending December 31, 2026. at the 2026-06-17 meeting.

“To ratify the appointment of Grassi & Co., CPAs, P.C, as the Company’s independent auditors for the fiscal year ending December 31, 2026. Votes For Votes Against Votes Abstained Broker Non-Vote 18,128,998 116,985 223,423 0”

Hepion Pharmaceuticals, Inc. shareholders approved Election of five director nominees: Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula and Chase LoPriore at the 2026-06-17 meeting.

“To elect the five (5) persons named herein as nominees for directors of the Company, to hold office until the next annual meeting of stockholders and until their respective successors have been duly elected and qualified consisting of Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula and Chase LoPriore. Name Votes For Withhold Broker Non-Vote Gary Stetz 13,498,755 153,947 4,816,704 Vincent LoPriore 13,492,507 160,195 4,816,704 Michael Purcell 13,186,912 465,790 4,816,704 Sireesh Appajosyula 13,503,469 149,233 4,816,704 Chase LoPriore 13,492,110 160,592 4,816,704”

Neonode Inc. shareholders approved Say-On-Pay Vote: Stockholders indicated their approval, on an advisory basis, of the compensation of the Company’s named executive officers. at the 2026-06-17 meeting.

“Proposal 3: Say-On-Pay Vote Stockholders indicated their approval, on an advisory basis, of the compensation of the Company’s named executive officers. The results of the votes were as follows: Proposal Votes For Votes Against Abstentions Broker Non-Votes Advisory vote on named executive officer compensation 5,919,473 160,182 643,947 2,371,599”

Neonode Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm: The stockholders ratified the selection Crowe LLP by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-17 meeting.

“Proposal 2: Ratification of Independent Registered Public Accounting Firm The stockholders ratified the selection Crowe LLP by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Proposal Votes For Votes Against Abstentions Broker Non-Votes Ratification of Crowe LLP as the Company’s independent registered public accounting firm 8,388,399 156,128 550,674 -”

Neonode Inc. shareholders approved Election of Directors: Each of Messrs. Peter Lindell and Per Löfgren was reelected to the Board of Directors for a three-year term as a Class III director. at the 2026-06-17 meeting.

“Proposal 1: Election of Directors Each of Messrs. Peter Lindell and Per Löfgren was reelected to the Board of Directors for a three-year term as a Class III director. The results of the votes were as follows: Proposal Votes For Withheld Broker Non-Votes Elect Peter Lindell to a three-year term to the Board of Directors 5,192,121 1,531,481 2,371,599 Elect Per Löfgren to a three-year term to the Board of Directors 5,944,694 778,908 2,371,599”

TWILIO INC shareholders approved Approve the Twilio Inc. Amended and Restated 2016 Employee Stock Purchase Plan. at the 2026-06-16 meeting.

“Proposal 5 - Approve the Twilio Inc. Amended and Restated 2016 Employee Stock Purchase Plan. The stockholders approved the Twilio Inc. Amended and Restated 2016 Employee Stock Purchase Plan. The results of such vote were: For Against Abstain Broker Non-Votes 118,850,839 398,239 43,095 11,845,816”

TWILIO INC shareholders approved Approve the Twilio Inc. Amended and Restated 2016 Stock Option and Incentive Plan. at the 2026-06-16 meeting.

“Proposal 4 - Approve the Twilio Inc. Amended and Restated 2016 Stock Option and Incentive Plan. The stockholders approved the Twilio Inc. Amended and Restated 2016 Stock Option and Incentive Plan. The results of such vote were: For Against Abstain Broker Non-Votes 88,949,992 30,250,610 91,571 11,845,816”

TWILIO INC shareholders approved Non-Binding Advisory Vote on Compensation of Named Executive Officers. at the 2026-06-16 meeting.

“Proposal 3 - Non-Binding Advisory Vote on Compensation of Named Executive Officers. The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The results of such vote were: For Against Abstain Broker Non-Votes 111,551,506 7,515,131 225,536 11,845,816”

TWILIO INC shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm - KPMG LLP for fiscal year ending December 31, 2026. at the 2026-06-16 meeting.

“Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of such vote were: For Against Abstain Broker Non-Votes 128,947,987 2,137,476 52,526 N/A”

TWILIO INC shareholders approved Election of Directors - to elect each of the four nominees as Class I directors. at the 2026-06-16 meeting.

“Proposal 1 - Election of Directors. The stockholders elected each of the four persons named below as Class I directors to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified. The results of such vote were: Director Nominee Votes For Votes Withheld Broker Non-Votes Charles Bell 118,662,184 629,989 11,845,816 Jeffrey Immelt 116,040,337 3,251,836 11,845,816 Douglas Robinson 118,171,168 1,121,005 11,845,816 Erika Rottenberg 115,400,239 3,891,934 11,845,816”

SeaStar Medical Holding Corp shareholders approved Approve adjournment or postponement of Annual Meeting to permit further solicitation if necessary at the 2026-06-17 meeting.

“Proposal 4 . To approve a proposal to adjourn or postpone the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if there are insufficient votes for, or otherwise in connection with, any of the proposals described above: Votes For Votes Against Abstentions Broker Non-Votes 2,035,262 123,747 21,905 —”

SeaStar Medical Holding Corp shareholders approved Ratify appointment of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.

“Proposal 3 . To ratify the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for the fiscal year ending December 31, 2026: Votes For Votes Against Abstentions Broker Non-Votes 2,151,096 22,746 7,072 —”

SeaStar Medical Holding Corp shareholders approved Approve amendment and restatement of 2022 Omnibus Incentive Plan to increase authorized shares from 207,046 to 896,546 at the 2026-06-17 meeting.

“Proposal 2 . To approve an amendment and restatement of the Company’s 2022 Omnibus Incentive Plan to increase the number of authorized shares of Common Stock from 207,046, as adjusted for a January 5, 2026, 1-for-10 reverse stock split, to 896,546: Votes For Votes Against Abstentions Broker Non-Votes 551,233 223,813 10,136 1,395,732”

SeaStar Medical Holding Corp shareholders approved Election of one Class I director to serve until the 2029 annual meeting of stockholders at the 2026-06-17 meeting.

“Proposal 1 . To elect one Class I director to serve until the 2029 annual meeting of stockholders, or until his successor shall have been duly elected and qualified: Nominee Votes For Votes Against Abstentions Broker Non-Votes John Neuman 757,141 23,212 4,829 1,395,732”

MADRIGAL PHARMACEUTICALS, INC. shareholders approved Approval of 2026 ESPP at the 2026-06-17 meeting.

“5. The Company’s stockholders approved the 2026 ESPP. The voting results were as follows: For Against Abstentions Broker Non-Votes 19,546,766 22,948 21,270 1,731,844”

MADRIGAL PHARMACEUTICALS, INC. shareholders approved Approval of 2026 Stock Plan at the 2026-06-17 meeting.

“4. The Company’s stockholders approved the 2026 Stock Plan. The voting results were as follows: For Against Abstentions Broker Non-Votes 19,118,851 446,394 25,739 1,731,844”

MADRIGAL PHARMACEUTICALS, INC. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditor at the 2026-06-17 meeting.

“3. The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: For Against Abstentions 21,256,315 37,505 29,009”

MADRIGAL PHARMACEUTICALS, INC. shareholders approved Advisory vote on executive compensation at the 2026-06-17 meeting.

“2. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. The voting results were as follows: For Against Abstentions Broker Non-Votes 19,000,895 561,058 29,031 1,731,844”

MADRIGAL PHARMACEUTICALS, INC. shareholders approved Election of Class I Directors at the 2026-06-17 meeting.

“1. The Company’s stockholders re-elected the three persons listed below as Class I directors, each to serve until the Company’s 2029 annual meeting of stockholders or until his successor is duly elected and qualified. The voting results were as follows: For Withheld Broker Non-Votes Julian C. Baker 17,363,250 2,227,734 1,731,844 Daniel J. Brennan 19,469,200 121,784 1,731,844 James M. Daly 18,921,185 669,799 1,731,844”

ImageneBio, Inc. shareholders approved 2025 Amended Plan at the 2026-06-16 meeting.

“Proposal 3: 2025 Amended Plan The Company’s stockholders approved the Amended Plan. The final voting results are as follows: For Against Abstain Broker Non-Votes 6,322,909 591,191 106,688 612,769”

ImageneBio, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-16 meeting.

“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: For Against Abstain 7,613,075 20,477 5”

ImageneBio, Inc. shareholders approved Election of Directors at the 2026-06-16 meeting.

“Proposal 1: Election of Directors The Company’s stockholders elected the following two individuals to serve as Class II directors, to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified or until his earlier death, resignation or removal. The final voting results are as follows: For Withheld Broker Non-Votes David P. Bonita, M.D. 6,980,671 40,117 612,769 Joseph P. Slattery 6,985,414 35,374 612,769”

Groupon, Inc. shareholders approved Approval of Amendment to Groupon's Restated Certificate of Incorporation to provide for officer exculpation as permitted by Section 102(b)(7) of the Delaware General Corporation Law at the 2026-06-11 meeting.

“Approval of Amendment to Groupon's Restated Certificate of Incorporation A proposal to approve an amendment to our Restated Certificate of Incorporation to provide for officer exculpation as permitted by Section 102(b)(7) of the Delaware General Corporation Law was approved with the following vote: For Against Abstentions Broker Non-Votes 20,606,190 491,355 236,982 5,661,810”

Groupon, Inc. shareholders approved Advisory Approval of Groupon's Named Executive Officer Compensation at the 2026-06-11 meeting.

“Advisory Approval of Groupon's Named Executive Officer Compensation A proposal to conduct a non-binding, advisory vote to approve our named executive officer compensation, as disclosed in the proxy statement, was approved with the following vote: For Against Abstentions Broker Non-Votes 20,771,441 338,086 225,000 5,661,810”

Groupon, Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm for Fiscal Year 2026 at the 2026-06-11 meeting.

“Ratification of Independent Registered Public Accounting Firm for Fiscal Year 2026 The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified with the following vote: For Against Abstentions 26,927,608 56,331 12,398”

Groupon, Inc. shareholders approved Election of Directors at the 2026-06-11 meeting.

“Election of Directors The Company's six director nominees were elected to the Board and will serve as directors until the Company's next annual meeting of stockholders or until their respective successors are elected and qualified. The directors were elected with the following vote: For Withheld Broker Non-Vote Dusan Senkypl 21,238,697 95,830 5,661,810 Jan Barta 20,986,018 348,509 5,661,810 Robert Bass 21,045,175 289,352 5,661,810 Jason Harinstein 21,218,650 115,877 5,661,810 Theodore Leonsis 20,157,886 1,176,641 5,661,810 Amit Shah 21,277,168 57,359 5,661,810”

REGENERON PHARMACEUTICALS, INC. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-12 meeting.

“Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement on Schedule 14A filed April 24, 2026 was approved based upon the following votes: For: 96,469,374 Against: 6,898,268 Abstain: 105,512 Broker Non-Votes: 5,543,411”

REGENERON PHARMACEUTICALS, INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-12 meeting.

“Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the following votes: For: 102,503,788 Against: 6,443,958 Abstain: 68,819”

REGENERON PHARMACEUTICALS, INC. shareholders approved Election of Directors at the 2026-06-12 meeting.

“Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: Nominee For Against Abstain Broker Non-Votes Joseph L. Goldstein, M.D. 72,398,297 30,904,254 170,603 5,543,411 Christine A. Poon 79,409,070 24,004,880 59,204 5,543,411 David P. Schenkein, M.D. 99,241,219 4,180,107 51,828 5,543,411 Craig B. Thompson, M.D. 81,933,651 21,378,567 160,936 5,543,411 Huda Y. Zoghbi, M.D. 100,665,234 2,698,397 109,523 5,543,411”

Zai Lab Ltd shareholders approved Approve general mandate to repurchase shares up to 10% at the 2026-06-17 meeting.

“Proposal 14 : An ordinary resolution to approve a general mandate to repurchase ordinary shares and/or ADSs of up to 10% of the total number of issued ordinary shares of the Company (excluding treasury shares) as of the date of the Annual Meeting until the 2027 annual general meeting of shareholders. For Against Abstentions Broker Non-Votes 547,258,396 25,670 2,997,801 - Accordingly, Proposal 14 was carried as an ordinary resolution.”

Zai Lab Ltd shareholders approved Approve general mandate to allot and issue shares up to 10% at the 2026-06-17 meeting.

“Proposal 13 : An ordinary resolution to approve a general mandate to the Board of Directors to allot and issue ordinary shares and/or ADSs and/or resell treasury shares of up to 10% of the total number of issued ordinary shares of the Company (excluding treasury shares) as of the date of the Annual Meeting until the 2027 annual general meeting of shareholders. For Against Abstentions Broker Non-Votes 546,131,045 1,077,021 3,073,801 - Accordingly, Proposal 13 was carried as an ordinary resolution.”

Zai Lab Ltd shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-17 meeting.

“Proposal 12 : An ordinary resolution to approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement. For Against Abstentions Broker Non-Votes 392,663,823 154,589,463 3,028,581 - Accordingly, the Company’s shareholders voted for an advisory vote on the compensation of the named executive officers, as disclosed in the Proxy Statement. Proposal 12 was carried as an ordinary resolution.”

Zai Lab Ltd shareholders approved Authorize the board to fix auditor compensation for 2026 at the 2026-06-17 meeting.

“Proposal 11 : An ordinary resolution to authorize the board of directors of the Company (the “Board of Directors”) to fix auditor compensation for 2026. For Against Abstentions Broker Non-Votes 546,562,816 714,770 3,004,281 - Accordingly, Proposal 11 was carried as an ordinary resolution.”

Zai Lab Ltd shareholders approved Approve the appointment of KPMG LLP and KPMG as auditors at the 2026-06-17 meeting.

“Proposal 10 : An ordinary resolution to approve the appointment of KPMG LLP and KPMG as the Company’s independent registered public accounting firms and auditors to audit our consolidated financial statements to be filed with the SEC and the Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) for the year ending December 31, 2026, respectively. For Against Abstentions Broker Non-Votes 547,252,626 29,640 2,999,601 - Accordingly, Proposal 10 was carried as an ordinary resolution.”

Zai Lab Ltd shareholders approved Re-election of nine directors to the Board at the 2026-06-17 meeting.

“Proposals 1 to 11 and 13 to 14 in the notice of the Annual Meeting were approved at the Annual Meeting.”

Biofrontera Inc. shareholders approved Ratification of appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-11 meeting.

“Stockholders ratified the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The tabulation of votes cast was as follows: For Against Abstain Broker Non-Votes 10,905,016 723,806 1,311 0”

Biofrontera Inc. shareholders approved Approval of amendment and restatement of the Company's 2021 Omnibus Incentive Plan, including to increase the total number of shares of common stock authorized thereunder from 3,750,000 to 8,750,000. at the 2026-06-11 meeting.

“Stockholders approved the amendment and restatement of the Company's 2021 Omnibus Incentive Plan, including to increase the total number of shares of common stock authorized thereunder from 3,750,000 to 8,750,000. The tabulation of votes cast was as follows: For Against Abstain Broker Non-Votes 7,893,236 241,359 175,881 3,319,657”